News About: Pharm. Affairs
Series of blockbuster drugs to be expired in patent at the year end
At the end of this year, a series of large blockbuster drugs including an antidiabetic ‘Twynsta’ will be expired in patent, and a follow-up great war of generics is about to occur.
According to the pharmaceutical ind...
“Our goal is to reduce antibiotic prescriptions by half in 5 years”
The government held the 86th National Policy Coordination Meeting hosted by Prime Minister Gyo-ahn Hwang at the Central Government Complex on the 11th, and confirmed the ‘National Antibiotic Resistance Management Plan...
Brilinta’s 1-year administration obstacle will be removed by low volume
The AstraZeneca’s anticoagulant Brilinta(generic name: ticagrelor) was also approved in a low volume, 60mg, followed by its 90mg volume.
Brilinta 90mg can only be prescribed for a year in combination with aspirin. H...
Oral rheumatoid arthritis therapy, Xeljanz, attempting for insurance as secondary treatment
An oral rheumatoid arthritis treatment ‘Xeljanz’ starts a move to recover its position as a practical secondary treatment.
According to the industry concerned on the 12th, the Pfizer’s janus kinase(JAK) inhibitor Xe...
‘Acute renal impairment’ warning added on Forxiga & Invokana
The Ministry of Food and Drug Safety(MFDS) gave an advance notice in regards to changes in the approval details of antidiabetic SGLT-2 inhibitors, ‘Forxiga(dapagliflozin)’ and ‘Invokana(canagliflozin)’ with the proces...
Series of domestic pharmaceuticals’ approvals to start global Phase 1 clinical trials
Domestic pharmaceutical companies are actively attempting to expand to the U.S. and European markets.
According to the industry concerned on the 10th, a series of news have continued about Phase 1 clinical trials ove...
Domestic pharm companies failed in patent challenges to leukemia therapy ‘Tasigna’
Domestic pharmaceutical companies challenged to a substance patent of ‘Tasigna,’ a Novartis’ chronic myelogenous leukemia therapy, but failed.
According to the industry on the 8th, Kukje Pharm and Navi Pharm applied ...
Abbvie’s another attempt to get health insurance benefit for ‘Duodopa’
A Parkinson’s disease treatment, ‘Duodopa Intestinal Gel,’ made the second challenge for the health insurance registration.
According to the industry concerned on the 9th, Abbvie’s Duodopa(carbidopa, levodopa) which...
Leading breast cancer therapy, Herceptin keeps exclusivity by next year
In the domestic breast cancer treatment market, the Roche’s influence is expected to be kept, at least, by 2017.
This is because Celltrion which acquire approval of the Herceptin’s biosimilar, ‘Herzuma,’ has recently...
Pharmaceutical distribution field nervous over fierce competition
While fierce competition among pharmaceutical distribution companies over clients is being developed, a concern was raised that survival cannot be guaranteed if companies are not able to adapt environmental changes. T...
